HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
AliveCor has spent years battling with Apple over the market for consumer heart monitoring technology. Now it’s hoping to make its imprint on professional health care with its new device, which ...
A "quasi-standard" multilead ECG can be recorded using just the Apple Watch, a report showed. The ECG function on the Watch is designed to monitor electrical activity of the heart in the direction of ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...
The company notes the synthesized output is not intended to replace a standard 12-lead ECG. HeartBeam also plans to advance development of an on-demand 12-lead ECG extended wear monitor and build ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback